Johnson & Johnson (JNJ) Falls Despite Earnings Beat, Strong Olysio Sales

NEW YORK (TheStreet) -- Johnson & Johnson  (JNJ) fell Tuesday despite its second-quarter earnings report that beat analysts' expectations.

The healthcare company reported a 9.1% revenue increase to $19.5 billion, while analysts polled by Thomson Reuters expected $19 billion. The company's hepatitis C treatment Olysio climbed to $831 million worldwide for the quarter, up from $354 million in the first quarter and greater than most estimates.

Johnson & Johnson reported earnings per share of $1.51 and adjusted EPS of $1.66. Analysts polled by Thomson Reuters expected $1.55 a share.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The company also increased its full-year earnings guidance, excluding items, to a range of $5.85 to $5.92, up from its previous forecast of $5.80 to $5.90 a share.

The stock was down 1.31% to $104 at 10:34 a.m.

JNJ Price Chart

JNJ Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect

If you liked this article you might like

Dow Drops Over 250 Points to End Six-Session Winning Streak

Dow Drops Over 250 Points to End Six-Session Winning Streak

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

The Decline In Johnson & Johnson Could Be Close to Being Over

The Decline In Johnson & Johnson Could Be Close to Being Over